周二，H.C. Wainwright维持了对Plus Therapeutics Inc. (NASDAQ:PSTV)的买入评级和8.00美元的股票目标价。这是在该公司于11月21日至24日举行的神经肿瘤学会年会上发表演讲之后。演讲内容包括了ReSPECT-LM第一阶段研究的最新进展，该研究评估了rhenium obisbemeda (186RNL)在治疗脑膜转移瘤 (LM)方面的效果。

Rhenium and technetium not only share the same group in the periodic table, but also have some common history relating to how they were — or indeed weren't — discovered. Eric Scerri explains.

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients ...